



Revlimid® (lenalidomide) – Expanded indication

- On February 22, 2017, the [FDA approved Celgene's Revlimid \(lenalidomide\)](#) for multiple myeloma (MM), as maintenance treatment following autologous hematopoietic stem cell transplantation (auto-HSCT).
 - Revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia outside of controlled clinical trials.
- Revlimid is also approved for MM, in combination with dexamethasone, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities, and mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included [Velcade® \(bortezomib\)](#).
- Efficacy for the expanded indication of Revlimid was based on two clinical studies enrolling 1,074 MM patients after auto-HSCT to Revlimid maintenance treatment or placebo. The primary efficacy endpoint was progression-free survival (PFS).
 - In study 1, a median PFS was demonstrated for Revlimid maintenance vs. placebo (5.7 years vs. 1.9 years; HR: 0.38 [95% CI: 0.28, 0.50]).
 - In study 2, a median PFS was demonstrated for Revlimid maintenance vs. placebo (3.9 years vs. 2.0 years; HR: 0.53 [95% CI: 0.44, 0.64]).
 - In addition, median overall survival was also demonstrated for Revlimid maintenance vs. placebo (Study 1: 9.3 years vs. 7 years (HR: 0.59 [95% CI: 0.44, 0.78]); Study 2: 8.8 years vs. 7.3 years (HR: 0.90 [95% CI: 0.72, 1.13])).
- Revlimid carries a boxed warning for embryo-fetal toxicity, hematologic toxicity, and venous and arterial thromboembolism.
- The most common adverse events (≥ 20%) with Revlimid use in MM patients were diarrhea, fatigue, anemia, constipation, neutropenia, leukopenia, peripheral edema, insomnia, muscle cramp/spasms, abdominal pain, back pain, nausea, asthenia, pyrexia, upper respiratory tract infection, bronchitis, nasopharyngitis, gastroenteritis, cough, rash, dyspnea, dizziness, decreased appetite, thrombocytopenia, and tremor.
- The recommended dose of Revlimid following auto-HSCT is 10 mg orally once daily (Days 1 - 28 of repeated 28-day cycles) until disease progression or unacceptable toxicity.
 - After 3 cycles of maintenance therapy, the dose may be increased to 15 mg once daily if tolerated.
 - Consult the Revlimid drug label for dosage recommendations for all other indications.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.